GP MDI (PT001) 14.4 μg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in COPD, Chronic Obstructive Pulmonary Disease

Drug Information

Target Indication

COPD, Chronic Obstructive Pulmonary Disease

Clinical Trial

Last updated: 8/1/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Related Pipeline

Psychosis Associated With Alzheimer's Disease

Inflammation

Effect of Treatment on Bone Mineral Density

Major Depressive Disorder

Hypercholesterolemia

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts